恶性胸膜间皮瘤的新型治疗策略
本文综述了恶性胸膜间皮瘤的新型治疗策略,包括免疫检查点抑制剂、其他免疫疗法、靶向治疗及新药联合方案,并讨论了如何选择最佳候选患者。标准化疗(顺铂联合培美曲塞)疗效有限,一线后无验证治疗,亟需新策略。
要点
- 免疫检查点抑制剂在化疗失败患者中显示潜在价值
- 贝伐珠单抗联合顺铂+培美曲塞显示一定前景
- 需关注新型治疗的最佳患者选择问题
核心结论
- 恶性胸膜间皮瘤标准一线化疗疗效有限,一线后无验证治疗,亟需新型治疗策略。
- 免疫检查点抑制剂等新型疗法在化疗失败患者中显示潜在价值,但最佳患者选择仍需探索。
研究设计与样本
- 本文为综述,描述了免疫检查点抑制剂、其他免疫疗法、靶向治疗或新药联合方案在恶性胸膜间皮瘤中的研究进展。
- 综述还讨论了选择这些治疗最佳候选患者的相关问题。
主要发现
- 贝伐珠单抗(抗VEGF抗体)联合顺铂加培美曲塞已显示一定前景。
- 免疫检查点抑制剂因数据提示对化疗失败患者有潜在价值而备受关注。
临床怎么用
- 目前标准一线治疗为顺铂联合培美曲塞化疗,但疗效短暂且不足。
- 一线后无验证治疗,可考虑临床试验中的免疫检查点抑制剂等新型疗法。
局限性
- 恶性胸膜间皮瘤为罕见癌症,通常与石棉暴露相关,患者预后差。
- 目前尚无治愈性治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Malignant pleural mesothelioma is a rare cancer that is typically associated with exposure to asbestos. Patients with malignant pleural mesothelioma have poor outcomes with suboptimal therapeutic options and currently no treatment is curative. The standard frontline treatment, cisplatin plus pemetrexed chemotherapy, has only short and insufficient efficacy, and no validated treatment beyond first-line therapy is available. New therapeutic strategies are therefore needed. The addition of bevacizumab (an anti-VEGF antibody) combined with cisplatin plus pemetrexed has shown some promise. However, immunotherapy, especially immune checkpoint inhibitors, has generated a lot of excitement because of data suggesting the potential value of immune checkpoint inhibitors for patients who have failed chemotherapy. In this Review, we describe immune checkpoint inhibitors, other immunotherapies, targeted therapies, or combinations of novel drugs being investigated in malignant pleural mesothelioma, as well as the issues surrounding the selection of the best candidates for these treatments.
引用
- Scherpereel A, Wallyn F, Albelda SM, et al. Novel therapies for malignant pleural mesothelioma. Lancet Oncol. 2018. PMID: 29508763. doi:10.1016/S1470-2045(18)30100-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。